Conflict of interest statement: Financial & competing interests disclosure AF 
Farago received consulting fees from PharmaMar, Bayer, Loxo, Abbvie, 
Abbvie/Stemcentrx and Genentech. The author further received research funding 
from PharmaMar, Bayer, Loxo, AbbVie, AbbVie/Stemcentrx, Merck, BMS, AstraZeneca 
and Novartis. BJ Drapkin received research funding from AstraZeneca, Novartis 
and AbbVie. JAL-Vilarino de Ramos, CM Golmarini, R Nunez, C Kahatt are employees 
of PharmaMar. L Paz-Ares gave scientific advice to Astra-Zeneca, BMS, MSD, 
Roche, Incyte, Takeda, Lilly, Novartis, Pfizer, Pharmamar, Amgen and Genomica. 
The manuscript arose, in whole or in part, from direct costs funded by NIH 
(grant number: K12 CA087723). The authors have no other relevant affiliations or 
financial involvement with any organization or entity with a financial interest 
in or financial conflict with the subject matter or materials discussed in the 
manuscript apart from those disclosed. No writing assistance was utilized in the 
production of this manuscript.